DaVita Inc. (NYSE:DVA) Receives Average Rating of “Hold” from Brokerages

DaVita Inc. (NYSE:DVA) has been assigned an average recommendation of “Hold” from the eight analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $221.75.

Several research analysts recently weighed in on DVA shares. Raymond James Financial set a $220.00 price target on shares of DaVita in a research report on Friday, August 7th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. UBS Group increased their target price on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Oppenheimer set a $220.00 target price on DaVita in a research report on Friday, August 7th. Finally, Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On DaVita

A number of hedge funds have recently modified their holdings of the business. Root Financial Partners LLC grew its stake in DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares in the last quarter. Caitlin John LLC purchased a new position in DaVita in the 4th quarter worth approximately $34,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita during the 2nd quarter worth approximately $43,000. Compass Financial Management LLC purchased a new stake in shares of DaVita in the second quarter valued at approximately $72,000. Finally, Sankala Group LLC purchased a new stake in shares of DaVita in the fourth quarter valued at approximately $39,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Price Performance

NYSE DVA traded up $0.56 on Monday, hitting $174.38. The company had a trading volume of 75,239 shares, compared to its average volume of 944,961. The company’s fifty day moving average price is $214.96 and its 200-day moving average price is $182.03. The company has a market capitalization of $11.13 billion, a PE ratio of 14.27, a PEG ratio of 0.58 and a beta of 0.88. DaVita has a 12-month low of $101.00 and a 12-month high of $247.49.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same period last year, the firm posted $2.95 earnings per share. The company’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts anticipate that DaVita will post 14.57 EPS for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.